The litigation, Mazzarino v. ADMA Biologics, Inc., stems from accusations that the pharmaceutical company engaged in channel stuffing and undisclosed related-party transactions to artificially inflate revenue figures. According to the complaint, these practices created a deceptive appearance of growth, leaving investors with a distorted view of the firm’s operational health and internal controls.
In section Releases
ADMA Biologics Faces Securities Fraud Lawsuit Following Revenue Claims
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, face an August 10, 2026, deadline to seek lead plaintiff status in a newly filed class action lawsuit. The case, currently pending in the U.S. District Court for the District of New Jersey, centers on allegations of misleading financial disclosures.
The scrutiny intensified on March 24, 2026, when Culper Research released a report alleging that ADMA induced distributors to stockpile excess product through rebates and extended payment terms. The report claimed this strategy allowed the company to book revenue for products that remained unsold. Following the report, ADMA shares plummeted 29.1% over two trading days, closing at $9.63 on March 25, 2026. Kessler Topaz Meltzer & Check, LLP is currently advising affected shareholders on their legal rights and potential recovery options.
Comments (0)
No comments yet. Be the first!